Reportlinker Adds AstraZeneca plc: PharmaVitae Profile

NEW YORK, April 1 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

AstraZeneca plc: PharmaVitae Profile

http://www.reportlinker.com/p0185092/AstraZeneca-plc-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for AstraZeneca in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark AstraZeneca's performance against key rivals in the prescription pharmaceutical sector

*Assess the commercial impact of AstraZeneca's recent movement into the biologics market, spearheaded by its acquisition of MedImmune

*Analyse the exposure of AstraZeneca's blockbuster portfolio to patent expiration and generic competition through to 2015

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly update 3

Company introduction 3

Company sales 4

Company financials 4

Key products 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2003-15 6

Financial performance, 2002-14 7

Note regarding full year 2009 financial data 7

AstraZeneca: PharmaVitae forecasts at a glance 8

Strategic insight 9

Highest material exposure to patent cliff in Big Pharma 9

Purity of blockbuster growth strategy facilitates high level of generic exposure 9

Overly dependent on small molecules 10

Exposed to cross-class therapeutic substitution 11

AstraZeneca cannot afford any more pipeline setbacks 11

MedImmune acquisition drives long term diversification into biologics and vaccines 14

Cost control essential to retain hope of profit growth 15

SWOT analysis 17

Strengths 18

Crestor franchise 18

Strong track record in cost control 18

Weaknesses 19

Over dependent on small molecules 19

Exposed to cross-class generic substitution 19

Recent history of pipeline failures 20

Over dependent on Crestor to drive 'Core' growth 20

Opportunities 20

Diversification into biologics and vaccines via MedImmune 20

Cost restructuring strategy 21

Potential blockbusters in late stage pipeline 21

Collaborations to boost near-medium term sales forecasts 22

Threats 23

Very high exposure to generic competition 23

No margin for failure in late stage R&D pipeline 23

Lack of strategic manoeuvrability stemming from MedImmune acquisition 23

Crestor patent case 23

TABLE OF CONTENTS 25

Table of figures 27

Chapter 3 Quarterly update 28

Latest comment 29

Q3 2009 29

AstraZeneca and Boehringer Ingelheim steal limelight at European Society of Cardiology meeting 29

Q2 2009 30

Merck and AstraZeneca: rivals join forces in oncology 30

Q1 2009 31

MAP Pharmaceuticals/AstraZeneca: setback for budesonide 31

AstraZeneca: nasal flu vaccine submitted for European approval 31

Latest prescription pharma product news 32

Q4 2009 32

Q3 2009 34

Q2 2009 36

Q1 2009 38

Latest corporate news 39

Q4 2009 39

Q3 2009 39

Q2 2009 39

Q1 2009 39

Future product milestones 40

Chapter 4 Company introduction 41

Key findings 41

Background 42

M&A history 42

Astra AB and Zeneca Group plc 42

Subsequent M&A activity 43

Abgenix 43

Cambridge Antibody Technology (CAT) 43

KuDOS Pharmaceuticals 43

Arrow Therapeutics 44

MedImmune 44

Albireo 44

M&A strategy 44

Chapter 5 Company sales 46

Key findings 46

Prescription pharmaceutical sales and growth rate analysis, 2003-15 47

Product analysis 48

Product analysis, 2003-09 50

Product analysis, 2009-15 52

Therapy area analysis 54

Geographic analysis 57

Launch/core/expiry analysis 59

Explanation of launch/core/expiry analysis 59

Launch analysis, 2009-15 60

Core analysis, 2009-15 61

Expiry analysis, 2009-15 62

Launch/core/expiry configuration, 2009-15 63

Molecule type analysis 64

Externalization analysis 66

Chapter 6 Company financials 68

Key findings 68

Note regarding full year 2009 financial data 69

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 69

Operating costs and profit analysis 70

Operating costs and profit analysis, 2002-08 71

Operating cost ratio and profit margin analysis, 2002-08 72

Operating cost ratio and profit margin analysis, 2008-14 73

Operating costs and profit analysis, 2008-14 74

Chapter 7 Key products 76

Overview 76

Crestor 77

Summary 78

Sales forecast 78

Brilinta 79

Summary 80

Sales forecast 80

Onglyza 81

Summary 81

Sales forecast 82

Certriad 82

Summary 83

Sales forecast 83

Dapagliflozin 84

Summary 84

Sales forecast 85

Seroquel 86

Summary 86

Sales forecast 87

Nexium 87

Summary 88

Sales forecast 88

Seloken/Toprol XL 89

Summary 89

Sales forecast 90

Pulmicort 90

Summary 91

Sales forecast 91

Arimidex 92

Summary 92

Sales forecast 93

Chapter 8 Appendix 94

References 94

Abbreviations 94

Exchange rates 95

About Datamonitor 96

About Datamonitor Healthcare 96

Datamonitor consulting 96

Disclaimer 98

LIST OF TABLES

Table 1: AstraZeneca - PharmaVitae forecasts at a glance 8

Table 2: AstraZeneca quarterly sales, Q408-Q409 28

Table 3: AstraZeneca future product milestones, 2010-12 40

Table 4: AstraZeneca product portfolio overview ($m), 2003-09 50

Table 5: AstraZeneca product portfolio overview ($m), 2009-15 52

Table 6: AstraZeneca prescription pharmaceutical sales by therapy area ($m), 2009-15 56

Table 7: AstraZeneca prescription pharmaceutical sales by geographic region ($m), 2009-15 58

Table 8: AstraZeneca launch portfolio overview ($m), 2009-15 60

Table 9: AstraZeneca core portfolio overview ($m), 2009-15 61

Table 10: AstraZeneca expiry portfolio overview ($m), 2009-15 62

Table 11: AstraZeneca prescription pharmaceutical sales by molecule type ($m), 2009-15 65

Table 12: AstraZeneca prescription pharmaceutical sales by source ($m), 2009-15 67

Table 13: Total AstraZeneca sales by business unit ($m), 2002-08 69

Table 14: AstraZeneca operating revenue/cost analysis ($m), 2002-08 71

Table 15: AstraZeneca operating cost ratio analysis (% of total revenues), 2002-08 72

Table 16: AstraZeneca operating cost ratio analysis (% of total revenues), 2008-14 73

Table 17: AstraZeneca operating revenue/cost analysis ($m), 2008-14 74

Table 18: AstraZeneca Key products overview 76

Table 19: Crestor: overview 78

Table 20: Crestor: sales forecast ($m), 2009-15 78

Table 21: Brilinta: overview 80

Table 22: Brilinta: sales forecast ($m), 2009-15 80

Table 23: Onglyza: overview 81

Table 24: Onglyza: sales forecast ($m), 2009-15 82

Table 25: Certriad: overview 83

Table 26: Certriad: sales forecast ($m), 2009-15 83

Table 27: Dapagliflozin: overview 84

Table 28: Dapagliflozin: sales forecast ($m), 2009-15 85

Table 29: Seroquel: overview 86

Table 30: Seroquel: sales forecast ($m), 2009-15 87

Table 31: Nexium: overview 88

Table 32: Nexium: sales forecast ($m), 2009-15 88

Table 33: Seloken/Toprol XL: overview 89

Table 34: Seloken/Toprol XL: sales forecast ($m), 2009-15 90

Table 35: Pulmicort: overview 91

Table 36: Pulmicort: sales forecast ($m), 2009-15 91

Table 37: Arimidex: overview 92

Table 38: Arimidex: sales forecast ($m), 2009-15 93

Table 39: Exchange rates, 2010 95

LIST OF FIGURES

Figure 1: The PharmaVitae Explorer 3

Figure 2: AstraZeneca prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 6

Figure 3: AstraZeneca's financial performance ($m), 2002-14 7

Figure 4: AstraZeneca prescription pharmaceutical sales by Launch/Core/Expiry classification ($m), 2009-15 9

Figure 5: AstraZeneca prescription pharmaceutical sales growth by portfolio component (blockbusters, rest of portfolio, new launches) ($m), 2003-15 10

Figure 6: AstraZeneca 2009 prescription pharmaceutical sales by global launch period ($m) 12

Figure 7: AstraZeneca operating revenue/cost analysis ($m), 2002-14 16

Figure 8: AstraZeneca SWOT analysis 17

Figure 9: AstraZeneca prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 47

Figure 10: AstraZeneca Key product sales ($m), 2003-15 48

Figure 11: AstraZeneca key sales growth drivers and resistors ($m), 2003-09 51

Figure 12: AstraZeneca key sales growth drivers and resistors ($m), 2009-15 53

Figure 13: AstraZeneca prescription pharmaceutical sales by therapy area ($m), 2003-15 54

Figure 14: AstraZeneca prescription pharmaceutical sales by geographic region ($m), 2003-15 57

Figure 15: AstraZeneca launch/core/expiry configuration ($m), 2009-15 63

Figure 16: AstraZeneca prescription pharmaceutical sales by molecule type ($m), 2003-15 64

Figure 17: AstraZeneca prescription pharmaceutical sales by source ($m), 2003-15 66

Figure 18: AstraZeneca operating revenue/cost analysis ($m), 2002-14 70

To order this report:

Pharmaceutical Industry: AstraZeneca plc: PharmaVitae Profile

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo